DCN and periampullary adenocarcinoma: In a recent study investigating associations between immune‐related serum markers and quality of life in the first 100 patients enrolled in the CHAMP study, a prospective, observational study of patients with PDAC and other periampullary cancers [2], decorin (DCN) was found to be among the top up‐regulated proteins after initiation of chemotherapy treatment.